Notice of Results

RNS Number : 5010G
Byotrol PLC
27 July 2021
 

 

 

 

 

 

 

 

 

 

Byotrol plc

 

("Byotrol" or the "Company")

 

Notice of results

 

 

 

Byotrol plc (AIM:BYOT) the specialist infection prevention and control company, will announce its audited results for the year ended 31 March 2021 on 19 August 2021.

 

 

Enquiries:

 

Byotrol plc 

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer                                                                    01925 742 000

 

finnCap

Geoff Nash/Kate Bannatyne - Corporate Finance  020 7220 0500

Richard Chambers - ECM

 

Flagstaff Strategic and Investor Communications

Tim Thompson/Andrea Seymour/Fergus Mellon   020 7129 1474

byotrol@flagstaffcomms.com

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORPPUBPMUPGGCQ
UK 100